A manufacturer of a general investigative treatment, or a manufacturer of an individualized investigative treatment operating within an eligible facility, may make the treatment available to an eligible patient, with or without compensation. An eligible facility, or a manufacturer operating within an eligible facility, may require an eligible patient to pay the costs of, or the costs associated with, the manufacture of the individualized investigative treatment. An eligible patient may request a general or individualized investigative treatment pursuant to this chapter. This chapter does not require a manufacturer or eligible facility to make available the general or individualized investigative treatment to an eligible patient.

Source: SL 2015, ch 188 , § 4; SL 2025, ch 144 , § 3.